Direkt zum Inhalt
Merck

Function of inhibitory micronetworks is spared by Na+ channel-acting anticonvulsant drugs.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2014-07-18)
Leonie Pothmann, Christina Müller, Robert G Averkin, Elisa Bellistri, Carolin Miklitz, Mischa Uebachs, Stefan Remy, Liset Menendez de la Prida, Heinz Beck
ZUSAMMENFASSUNG

The mechanisms of action of many CNS drugs have been studied extensively on the level of their target proteins, but the effects of these compounds on the level of complex CNS networks that are composed of different types of excitatory and inhibitory neurons are not well understood. Many currently used anticonvulsant drugs are known to exert potent use-dependent blocking effects on voltage-gated Na(+) channels, which are thought to underlie the inhibition of pathological high-frequency firing. However, some GABAergic inhibitory neurons are capable of firing at very high rates, suggesting that these anticonvulsants should cause impaired GABAergic inhibition. We have, therefore, studied the effects of anticonvulsant drugs acting via use-dependent block of voltage-gated Na(+) channels on GABAergic inhibitory micronetworks in the rodent hippocampus. We find that firing of pyramidal neurons is reliably inhibited in a use-dependent manner by the prototypical Na(+) channel blocker carbamazepine. In contrast, a combination of intrinsic and synaptic properties renders synaptically driven firing of interneurons essentially insensitive to this anticonvulsant. In addition, a combination of voltage imaging and electrophysiological experiments reveal that GABAergic feedforward and feedback inhibition is unaffected by carbamazepine and additional commonly used Na(+) channel-acting anticonvulsants, both in control and epileptic animals. Moreover, inhibition in control and epileptic rats recruited by in vivo activity patterns was similarly unaffected. These results suggest that sparing of inhibition is an important principle underlying the powerful reduction of CNS excitability exerted by anticonvulsant drugs.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
Bromwasserstoffsäure, ACS reagent, 48%
Sigma-Aldrich
Mitomycin C aus Streptomyces caespitosus, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
Bromwasserstoffsäure, reagent grade, 48%
Sigma-Aldrich
Hydrogenbromid -Lösung, 33 wt. % in acetic acid
Sigma-Aldrich
Mitomycin C aus Streptomyces caespitosus, powder, contains NaCl as solubilizer
Sigma-Aldrich
Carbamazepin, powder
Sigma-Aldrich
Bromwasserstoffsäure, 48 wt. % in H2O, ≥99.99%
Sigma-Aldrich
Pilocarpin -hydrochlorid, ≥99% (titration), powder
Sigma-Aldrich
Mitomycin C aus Streptomyces caespitosus, ≥98% (HPLC), γ-irradiated, suitable for cell culture
Sigma-Aldrich
Mitomycin C aus Streptomyces caespitosus, meets USP testing specifications
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Sigma-Aldrich
Pilocarpin -nitrat (Salz), ≥98% (HPLC)
Supelco
Carbamazepin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Carbamazepine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Carbamazepin, analytical standard
USP
Phenytoin, United States Pharmacopeia (USP) Reference Standard
USP
Carbamazepin, United States Pharmacopeia (USP) Reference Standard
Ketamin -hydrochlorid, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Carbamazepin, meets USP testing specifications
Phenytoin, European Pharmacopoeia (EP) Reference Standard
Pilocarpin -hydrochlorid, European Pharmacopoeia (EP) Reference Standard
Carbamazepin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Pilocarpin -nitrat, meets USP testing specifications
Phenytoin für die Systemeignung, European Pharmacopoeia (EP) Reference Standard
Pilocarpinnitrat, European Pharmacopoeia (EP) Reference Standard
Pilocarpinnitrat für die Systemeignung, European Pharmacopoeia (EP) Reference Standard